A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05653882 |
|
Recruitment Status :
Recruiting
First Posted : December 16, 2022
Last Update Posted : May 13, 2024
|
Sponsor:
Asher Biotherapeutics, Inc.
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Asher Biotherapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 2026 |
| Estimated Study Completion Date : | May 2027 |